Indeed, DPP-4 activity in the circulation has been reported to be reduced in rodents or humans treated with metformin [14, 15]
Without the right medical supervision, patients can struggle with side effects, improper dosing, and hitting frustrating plateaus
Researchers have observed that it stimulates growth hormone release from anterior pituitary somatotrophs without significantly affecting cortisol, prolactin, or adrenocorticotropic hormone (ACTH) levels a selectivity profile that has made it one of the most widely studied GHRPs in preclinical research
[4] The FDA label also provides guidance on when to consider discontinuation: if a patient has not lost at least 5% of their initial body weight after 12 weeks on the 2.4 mg dose, stopping treatment may be appropriate as further benefits are unlikely
This creates maximum precision for small doses, making it ideal for microdosing protocols or researchers who prioritize measurement accuracy above all else